Download these slides from a live Webinar to gain expert insight on the rationale for combining PARP inhibitors and AR-directed therapy in mCRPC including the latest evidence from ASCO GU 2021.
This downloadable slide set from a live Webinar explores the rationale for combining PARP inhibitors with different types of agents for advanced prostate cancer, including immunotherapy, targeted agents, and radionuclides, incorporating the latest evidence from ASCO GU 2021.
Download these slides from a live Webinar to review the most recent clinical data on single-agent PARP inhibitors in metastatic castration-resistant prostate cancer
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA
Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.